April 10, 2015 — As the chief executive officer of the Bill &
Melinda Gates Foundation, Sue Desmond-Hellmann leads a multi-billion
dollar effort to improve health and promote equity for all people around the
world. Speaking to a Harvard T.H. Chan School of Public Health audience on
World Health Day, April 7, 2015, Desmond-Hellmann recalled her own idealistic
student days and made the case for pursuing big ambitions in public health. Her
talk was part of the Dean’s
Distinguished Lecture series.
Desmond-Hellmann shared the “Big Bet,” an
ambitious series of goals issued by Bill and Melinda Gates in their annual
letter marking this year’s 15th anniversary of the Foundation. It
states that, “The lives of people in poor countries will improve faster in the
next 15 years than at any other time in history. And their lives will improve
more than anyone else’s.” Desmond-Hellman challenged Harvard Chan students to
help make it a reality.
“I do think it is impatient
optimism, but it’s not crazy,” she said, and quoted the Foundation’s favorite African
proverb: “If you want to go fast, go alone. If you want to go far, go
together.”
Desmond-Hellmann praised the
often unsung work of epidemiologists, stating that she believes that the
best innovations in public health develop from thinking like they do — with an
understanding of the patterns and causes of disease.
These days, she is particularly
excited about innovations in health care delivery and in promoting behavior
change, she said. Two recent examples are the Foundation’s work providing seed
funding and support to GAVI, a global alliance to increase access to vaccines for
children living in the world’s poorest countries, and the transformation of the
Foundation’s polio operations center in Nigeria into an emergency Ebola care
center within just 12 hours, in July after an outbreak was detected in the city
of Lagos.
Desmond-Hellmann spoke about the
often tough decisions that the Foundation has to make in determining what to
fund, and noted that she tries to look for areas where it is uniquely positioned
to make a difference, such as infectious disease eradication and maternal
health.
Prior to joining the Foundation
in 2014, Desmond-Hellmann served as chancellor of the University of California at San
Francisco, where she remains a tenured professor. An oncologist, her
work in research and development at Genentech helped bring breakthrough cancer drugs
to the marketplace.
Dean Julio Frenk praised her
depth of experience in his introductory remarks, noting, that “Sue personifies
all the career paths that any of our students could hope to achieve in one
lifetime.”
No comments:
Post a Comment